Redeye retains its positive view of Addnode following the Q3 report, showing solid development in PLM and PM, while DM came in slightly short of our expectations. We leave our Base Case unchanged. Following recent value-driving acquisitions and the lower share price, we believe the risk/reward has improved since our Q2 Update.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/